Remdesivir, the First Coronavirus Drug, Gets a Price Tag

 Federal  health officials and Gilead Sciences have settled on priority distribution to Americans — and nonnegotiable pricing.
Remdesivir, the primary medication demonstrated to be powerful against the coronavirus, will be appropriated under a surprising concurrence with the government that sets up nonnegotiable costs and prioritizes  American patients, Health authorities declared on Monday.  

The arrangements may serve as a layout for conveyance of new medicines and immunizations as the pandemic continue, said Ernst Berndt, a retired health economist analyst at the Massachusetts Institute of Technology Sloan School of Management.  

Remdesivir will be sold for $520 per vial, or $3,120 per treatment course, to clinics for treatment of patients with private protection, according to Department of Health and Human Services and Gilead Sciences, the medication's producer.  

The cost will be set at $390 per vial, or $2,340 per treatment course, for patients on government-supported protection and for those in different nations with national social insurance frameworks. 

The medication will be sold uniquely in the United States through September, which means American patients will get nearly the whole of Gilead's yield, in excess of 500,000 treatment courses.

 New York Times from NYT Health

Post a comment